Article Text

Download PDFPDF
A rotavirus vaccine for infants prevented rotavirus gastroenteritis with no increase in risk of intussusception

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Q In healthy infants, does a rotavirus vaccine prevent rotavirus gastroenteritis and reduce use of healthcare resources without i

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Public health ★★★★★★★


Embedded ImageDesign:

randomised controlled trial.

Embedded ImageAllocation:

unclear allocation concealment.*

Embedded ImageBlinding:

blinded (parents, healthcare providers, outcome assessors, and sponsors).*

Embedded ImageFollow up period:

1 year (through ⩾1 full rotavirus season).

Embedded ImageSetting:

hundreds of centres in the US, Taiwan, Europe, and Central America.

Embedded ImageParticipants:

69 274 healthy infants 6–12 weeks of age (mean age 10 wks, 51% boys) without recent (⩽42 d) or planned use of oral poliovirus vaccine.

Embedded ImageIntervention:

oral, live pentavalent (G1, G2, G3, G4, and P[8]) human bovine (WC3) reassortant rotavirus vaccine (n  =  34 644) or placebo (n  =  34 630), 3 doses 4–10 weeks apart. Parents were contacted regularly to ascertain adverse events and cases of gastroenteritis.

Embedded ImageOutcomes:

intussusception, other serious adverse …

View Full Text


  • * See glossary.

  • For correspondence: Dr P Heaton Mereck Research Laboratories, West Point, PA, USA. Penny_heaton{at}

  • Source of funding: Mereck